Novavax shares rose 2.47% in premarket trading.
Canada on Thursday approved Novavax Inc's COVID-19 vaccine for people aged 18 years and older, making it the fifth such shot to be cleared for use in the country.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments